{
    "xml": "<topic id=\"PHP96722\" outputclass=\"drug\" rev=\"1.16\" type=\"drug\" namespace=\"/drugs/epoetin-zeta\" basename=\"epoetin-zeta\" title=\"EPOETIN ZETA\">\n<title>EPOETIN ZETA</title>\n<body>\n<data name=\"vtmid\">428902004</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_871130604\" title=\"Epoetins\">Epoetins</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34585\" title=\"EPOETINS\" namespace=\"/drug-classes/epoetins\">EPOETINS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP96814\" outputclass=\"indicationsAndDose\" rev=\"1.34\" parent=\"/drugs/epoetin-zeta\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptomatic anaemia associated with chronic renal failure in patients on haemodialysis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection or by subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 50&#8239;units/kg 3 times a week, adjusted according to response, adjusted in steps of 25&#8239;units/kg 3 times a week, dose to be adjusted at intervals of at least 4 weeks; maintenance 25&#8211;100&#8239;units/kg 3 times a week, intravenous injection to be given over 1&#8211;5 minutes, if given by subcutaneous injection, a maximum of 1&#8239;mL can be given per injection site, avoid increasing haemoglobin concentration at a rate exceeding 2&#8239;g/100&#8239;mL over 4 weeks.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptomatic anaemia associated with chronic renal failure in adults on peritoneal dialysis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection or by subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 50&#8239;units/kg twice weekly; maintenance 25&#8211;50&#8239;units/kg twice weekly, intravenous injection to be given over 1&#8211;5 minutes, if given by subcutaneous injection, a maximum of 1&#8239;mL can be given per injection site, avoid increasing haemoglobin concentration at a rate exceeding 2&#8239;g/100&#8239;mL over 4 weeks.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe symptomatic anaemia of renal origin in adults with renal insufficiency not yet on dialysis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection or by subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 50&#8239;units/kg 3 times a week, adjusted according to response, adjusted in steps of 25&#8239;units/kg 3 times a week, dose to be increased at intervals of at least 4 weeks; maintenance 17&#8211;33&#8239;units/kg 3 times a week (max. per dose 200&#8239;units/kg 3 times a week), intravenous injection to be given over 1&#8211;5 minutes, if given by subcutaneous injection, a maximum of 1&#8239;mL can be given per injection site, avoid increasing haemoglobin concentration at a rate exceeding 2&#8239;g/100&#8239;mL over 4 weeks.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptomatic anaemia in adults receiving cancer chemotherapy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 150&#8239;units/kg 3 times a week, alternatively initially 450&#8239;units/kg once weekly, increased to 300&#8239;units/kg 3 times a week, only increase dose if appropriate rise in haemoglobin (or reticulocyte count) not achieved after 4 weeks; discontinue if inadequate response after 4 weeks at higher dose, maximum 1&#8239;mL per injection site, reduce dose by approximately 25&#8211;50% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks or if haemoglobin concentration exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">To increase yield of autologous blood (to avoid homologous blood) in predonation programme in moderate anaemia either when large volume of blood required or when sufficient blood cannot be saved for elective major surgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>600&#8239;units/kg twice weekly for 3 weeks before surgery, intravenous injection to be given over 1&#8211;5 minutes, consult product literature for details and advice on ensuring high iron stores.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Moderate anaemia (haemoglobin concentration 10&#8211;13&#8239;g/100&#8239;mL) before elective orthopaedic surgery in adults with expected moderate blood loss to reduce exposure to allogeneic blood transfusion or if autologous transfusion unavailable</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>600&#8239;units/kg every 1&#8239;week for 3 weeks before surgery and on day of surgery, alternatively 300&#8239;units/kg daily for 15 days starting 10 days before surgery, maximum 1&#8239;mL per injection site, consult product literature for details.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP96816\" outputclass=\"pregnancy\" parent=\"/drugs/epoetin-zeta\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>No evidence of harm.</p>\n<p>Benefits probably outweigh risk of anaemia and of blood transfusion in pregnancy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP96806\" outputclass=\"breastFeeding\" parent=\"/drugs/epoetin-zeta\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Unlikely to be present in milk.</p>\n<p>Minimal effect on infant.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP96813\" outputclass=\"hepaticImpairment\" parent=\"/drugs/epoetin-zeta\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturers advise caution in chronic hepatic failure.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP96828\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.8\" parent=\"/drugs/epoetin-zeta\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Products containing epoetin zeta are not identical and although there should be no important differences in terms of safety and efficacy, when prescribing biological products it is good practice to use the brand name.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP96827\" outputclass=\"nationalFunding\" rev=\"1.19\" parent=\"/drugs/epoetin-zeta\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA323</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014)</p>\r\n<p>Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.</p>\r\n<p>If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA323\">www.nice.org.uk/TA323</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP96722-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/epoetin-zeta\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP96834\" title=\"Solution for injection\" namespace=\"/drugs/epoetin-zeta/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34585\" namespace=\"/drug-classes/epoetins\" title=\"EPOETINS\" count=\"1\" rel=\"link\">EPOETINS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP96834\" namespace=\"/drugs/epoetin-zeta/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP96722",
    "outputclass": "drug",
    "rev": "1.16",
    "type": "drug",
    "namespace": "/drugs/epoetin-zeta",
    "basename": "epoetin-zeta",
    "title": "EPOETIN ZETA",
    "vtmid": "428902004",
    "drugClassification": [
        "Epoetins"
    ],
    "inheritsFromClass": [
        "EPOETINS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Symptomatic anaemia associated with chronic renal failure in patients on haemodialysis",
                        "html": "Symptomatic anaemia associated with chronic renal failure in patients on haemodialysis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection or subcutaneous injection"
                    ],
                    "textContent": "By intravenous injection or by subcutaneous injection",
                    "html": "By intravenous injection or by subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 50 units/kg 3 times a week, adjusted according to response, adjusted in steps of 25 units/kg 3 times a week, dose to be adjusted at intervals of at least 4 weeks; maintenance 25&#8211;100 units/kg 3 times a week, intravenous injection to be given over 1&#8211;5 minutes, if given by subcutaneous injection, a maximum of 1 mL can be given per injection site, avoid increasing haemoglobin concentration at a rate exceeding 2 g/100 mL over 4 weeks.",
                        "html": "<p>Initially 50&#8239;units/kg 3 times a week, adjusted according to response, adjusted in steps of 25&#8239;units/kg 3 times a week, dose to be adjusted at intervals of at least 4 weeks; maintenance 25&#8211;100&#8239;units/kg 3 times a week, intravenous injection to be given over 1&#8211;5 minutes, if given by subcutaneous injection, a maximum of 1&#8239;mL can be given per injection site, avoid increasing haemoglobin concentration at a rate exceeding 2&#8239;g/100&#8239;mL over 4 weeks.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Symptomatic anaemia associated with chronic renal failure in adults on peritoneal dialysis",
                        "html": "Symptomatic anaemia associated with chronic renal failure in adults on peritoneal dialysis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection or subcutaneous injection"
                    ],
                    "textContent": "By intravenous injection or by subcutaneous injection",
                    "html": "By intravenous injection or by subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 50 units/kg twice weekly; maintenance 25&#8211;50 units/kg twice weekly, intravenous injection to be given over 1&#8211;5 minutes, if given by subcutaneous injection, a maximum of 1 mL can be given per injection site, avoid increasing haemoglobin concentration at a rate exceeding 2 g/100 mL over 4 weeks.",
                        "html": "<p>Initially 50&#8239;units/kg twice weekly; maintenance 25&#8211;50&#8239;units/kg twice weekly, intravenous injection to be given over 1&#8211;5 minutes, if given by subcutaneous injection, a maximum of 1&#8239;mL can be given per injection site, avoid increasing haemoglobin concentration at a rate exceeding 2&#8239;g/100&#8239;mL over 4 weeks.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Severe symptomatic anaemia of renal origin in adults with renal insufficiency not yet on dialysis",
                        "html": "Severe symptomatic anaemia of renal origin in adults with renal insufficiency not yet on dialysis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection or subcutaneous injection"
                    ],
                    "textContent": "By intravenous injection or by subcutaneous injection",
                    "html": "By intravenous injection or by subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 50 units/kg 3 times a week, adjusted according to response, adjusted in steps of 25 units/kg 3 times a week, dose to be increased at intervals of at least 4 weeks; maintenance 17&#8211;33 units/kg 3 times a week (max. per dose 200 units/kg 3 times a week), intravenous injection to be given over 1&#8211;5 minutes, if given by subcutaneous injection, a maximum of 1 mL can be given per injection site, avoid increasing haemoglobin concentration at a rate exceeding 2 g/100 mL over 4 weeks.",
                        "html": "<p>Initially 50&#8239;units/kg 3 times a week, adjusted according to response, adjusted in steps of 25&#8239;units/kg 3 times a week, dose to be increased at intervals of at least 4 weeks; maintenance 17&#8211;33&#8239;units/kg 3 times a week (max. per dose 200&#8239;units/kg 3 times a week), intravenous injection to be given over 1&#8211;5 minutes, if given by subcutaneous injection, a maximum of 1&#8239;mL can be given per injection site, avoid increasing haemoglobin concentration at a rate exceeding 2&#8239;g/100&#8239;mL over 4 weeks.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Symptomatic anaemia in adults receiving cancer chemotherapy",
                        "html": "Symptomatic anaemia in adults receiving cancer chemotherapy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 150 units/kg 3 times a week, alternatively initially 450 units/kg once weekly, increased to 300 units/kg 3 times a week, only increase dose if appropriate rise in haemoglobin (or reticulocyte count) not achieved after 4 weeks; discontinue if inadequate response after 4 weeks at higher dose, maximum 1 mL per injection site, reduce dose by approximately 25&#8211;50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy.",
                        "html": "<p>Initially 150&#8239;units/kg 3 times a week, alternatively initially 450&#8239;units/kg once weekly, increased to 300&#8239;units/kg 3 times a week, only increase dose if appropriate rise in haemoglobin (or reticulocyte count) not achieved after 4 weeks; discontinue if inadequate response after 4 weeks at higher dose, maximum 1&#8239;mL per injection site, reduce dose by approximately 25&#8211;50% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks or if haemoglobin concentration exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "To increase yield of autologous blood (to avoid homologous blood) in predonation programme in moderate anaemia either when large volume of blood required or when sufficient blood cannot be saved for elective major surgery",
                        "html": "To increase yield of autologous blood (to avoid homologous blood) in predonation programme in moderate anaemia either when large volume of blood required or when sufficient blood cannot be saved for elective major surgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection"
                    ],
                    "textContent": "By intravenous injection",
                    "html": "By intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "600 units/kg twice weekly for 3 weeks before surgery, intravenous injection to be given over 1&#8211;5 minutes, consult product literature for details and advice on ensuring high iron stores.",
                        "html": "<p>600&#8239;units/kg twice weekly for 3 weeks before surgery, intravenous injection to be given over 1&#8211;5 minutes, consult product literature for details and advice on ensuring high iron stores.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Moderate anaemia (haemoglobin concentration 10&#8211;13 g/100 mL) before elective orthopaedic surgery in adults with expected moderate blood loss to reduce exposure to allogeneic blood transfusion or if autologous transfusion unavailable",
                        "html": "Moderate anaemia (haemoglobin concentration 10&#8211;13&#8239;g/100&#8239;mL) before elective orthopaedic surgery in adults with expected moderate blood loss to reduce exposure to allogeneic blood transfusion or if autologous transfusion unavailable"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "600 units/kg every 1 week for 3 weeks before surgery and on day of surgery, alternatively 300 units/kg daily for 15 days starting 10 days before surgery, maximum 1 mL per injection site, consult product literature for details.",
                        "html": "<p>600&#8239;units/kg every 1&#8239;week for 3 weeks before surgery and on day of surgery, alternatively 300&#8239;units/kg daily for 15 days starting 10 days before surgery, maximum 1&#8239;mL per injection site, consult product literature for details.</p>"
                    }
                ]
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "No evidence of harm.\n\nBenefits probably outweigh risk of anaemia and of blood transfusion in pregnancy.",
                "html": "<p>No evidence of harm.</p><p>Benefits probably outweigh risk of anaemia and of blood transfusion in pregnancy.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Unlikely to be present in milk.\n\nMinimal effect on infant.",
                "html": "<p>Unlikely to be present in milk.</p><p>Minimal effect on infant.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturers advise caution in chronic hepatic failure.",
                "html": "<p>Manufacturers advise caution in chronic hepatic failure.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Products containing epoetin zeta are not identical and although there should be no important differences in terms of safety and efficacy, when prescribing biological products it is good practice to use the brand name.",
                "html": "<p>Products containing epoetin zeta are not identical and although there should be no important differences in terms of safety and efficacy, when prescribing biological products it is good practice to use the brand name.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA323",
                        "label": "www.nice.org.uk/TA323"
                    }
                ],
                "fundingIdentifier": "NICE TA323",
                "textContent": "Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014) Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy. If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.\n\nwww.nice.org.uk/TA323",
                "html": "<p outputclass=\"title\">Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014)</p> <p>Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.</p> <p>If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA323\">www.nice.org.uk/TA323</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP96834",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "drugClass": [
            {
                "id": "PHP34585",
                "label": "EPOETINS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP96834",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}